<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367797">
  <stage>Registered</stage>
  <submitdate>23/01/2015</submitdate>
  <approvaldate>7/09/2016</approvaldate>
  <actrnumber>ACTRN12616001248459</actrnumber>
  <trial_identification>
    <studytitle>The use of metformin in patients with moderate to severe renal failure and type 2 diabetes</studytitle>
    <scientifictitle>A pharmacokinetic study of metformin in patients with stable stage 4 chronic kidney disease and type 2 diabetes</scientifictitle>
    <utrn>U1111-1166-3205 </utrn>
    <trialacronym />
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes mellitus</healthcondition>
    <healthcondition>Chronic Kidney Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intervention: Low dose metformin of 250mg, 500mg and 1000mg per day.  Patients in cohort 1 will take 250mg dose.  When this cohort has completed treatment cohort 2 will commence.  Patients in cohort 2 will take a 500mg dose.  After completion of cohort 2, patients in cohort 3 will commence and take the 1000mg dose.
Duration: 4 weeks
Method of administration: Oral
Adherence monitoring: Pill count and drug plasma level monitoring</interventions>
    <comparator>Active
Participants to remain on current diabetic medication as per standard care</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Trough metformin serum concentrations using high performance liquid chromatography (HPLC)</outcome>
      <timepoint>Weekly levels for 4 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Single dose pharmacokinetic profile for metformin in patients with stage 4 chronic kidney disease using HPLC assay to measure serum metformin concentrations at 0, 2, 4, 6 ,8 and 24 hours.</outcome>
      <timepoint>Day 4 at 0, 2, 4, 6 ,8 and 24 hours.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>72 hour continuous capillary glucose monitoring using an implanted Continuous Glucose Control Monitoring System (CGMS) with the sensor inserted subcutaneously into the abdominal wall.</outcome>
      <timepoint>Day 1-3 and Day 29-31</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hemoglobin A1c serum assay</outcome>
      <timepoint>Day 1 and Day 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum lactate levels</outcome>
      <timepoint>Day 1, 11, 18, 25, 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum bicarbonate levels</outcome>
      <timepoint>Day 1, 11, 18, 25, 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Venous pH via venous blood gas</outcome>
      <timepoint>Day 1, 11, 18, 25, 32</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Type 2 diabetes for at least 2 years
2. Haemoglobin A1c between 6 and 11%
3. Stable stage 4 chronic kidney disease as defined by estimated glomerular filtration rate of 15-29mls/1.73m2.</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Current treatment with metformin
2. Previous intolerance to metformin
3. Body mass greater than 160kg
4. Severe COPD as evidenced by hospitalization for decompensation within 6 months of randomization, chronic treatment with oral steroids 
5.  Unstable CHF needing frequent hospitalisations or frequent adjustment of heart failure medications
6.  Significant IHD with acute coronary event, and/or CABG, and/or PCI in the previous 60 days.
7.  Severe liver disease with icterus and plasma bilirubin  greater than or equal to 60 micrommol/L, plasma transaminase greater than 3-fold upper limit of normal, albumin  less than 25 g/L or coagulopathy.
8.  Haemoglobin  less tha 100 g/L or platelet count less than 80,000/mm3
9.  Gastrointestinal bleeding in the previous 60 days
10.  Unstable angina or planned for invasive cardiac investigations in the next 6 months  
11.  Malignancy other than basal cell carcinoma.
12.  Any other disease or condition which in the opinion of the investigator could make them unsuitable for entry.
13.  Pregnant, nursing a child, or planning a pregnancy at the time of this study
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>7/05/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>3/03/2014</actualenddate>
    <samplesize>18</samplesize>
    <actualsamplesize>18</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>3/04/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Ajith Dissanayake</primarysponsorname>
    <primarysponsoraddress>Department of Medicine
Middlemore Hospital
Hospital Rd
Papatoetoe, Auckland 2025</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Middlemore Clinical Trials</fundingname>
      <fundingaddress>Middlemore Clinical trials
Esme Green Building
Middlemore Hospital
Hospital Rd
Papatoetoe, Auckland 2025</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Christopher Hood</sponsorname>
      <sponsoraddress>Renal Department
Middlemore Hospital
Hospital Rd
Papatoetoe, Auckland 2025</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary goal of this study was to establish if treatment with low dose metformin in patients with stage 4 chronic kidney disease would produce safe and therapeutic serum levels of metformin.  Metformin is widely acknowledged to be the first choice treatment for type 2 diabetes mellitus but fears around accumulation in patients with kidney disease have limited it's use in this patient group.  Our aim is to investigate the use of low dose metformin in this group by showing predictable, stable and safe drug levels with low dose treatment.</summary>
    <trialwebsite />
    <publication>Manuscript in preparation</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern X Regional Ethics Committee, Health and Disability Ethics Committees</ethicname>
      <ethicaddress>Private Bag 92522
Wellesley Street
Auckland 1141
</ethicaddress>
      <ethicapprovaldate>19/12/2011</ethicapprovaldate>
      <hrec>NTX/11/12/112</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Christopher Hood</name>
      <address>Middlemore Hospital Private Bag 93311 Otahuhu Auckland 1640</address>
      <phone>+64 9 276 0000</phone>
      <fax />
      <email>chris.hood@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Christopher Hood</name>
      <address>Middlemore Hospital Private Bag 93311 Otahuhu Auckland 1640</address>
      <phone>+64 9 276 0000</phone>
      <fax />
      <email>chris.hood@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Christopher Hood</name>
      <address>Middlemore Hospital Private Bag 93311 Otahuhu Auckland 1640</address>
      <phone>+64 9 276 0000</phone>
      <fax />
      <email>chris.hood@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Christopher Hood</name>
      <address>Middlemore Hospital Private Bag 93311 Otahuhu Auckland 1640</address>
      <phone>+64 9 276 0000</phone>
      <fax />
      <email>chris.hood@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>